Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBoston Scientific PROMUS and First-Generation TAXUS Express Stents Continue Excellent Performance in SPIRIT III Trial
Boston Scientific, 09/22/09
Boston Scientific Corporation welcomed three–year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long–term safety of the Company's portfolio of drug–eluting stents, including the first–generation TAXUS Express(2)™ Paclitaxel–Eluting Coronary Stent System and the XIENCE V™ Everolimus–Eluting Coronary Stent System.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor